PATENT CLAIM ANALYSIS

Application Number: 15749485
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["514", "357000"]

Abstract:
The present invention relates to a composition for use in treating a glioma or ameliorating the effects of a glioma, particularly glioblastoma, wherein said composition comprises a first active agent selected from the group consisting of a compound of formula (I), or a pharmaceutically acceptable salt thereof, (I) and a second active agent, which is temozolomide, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

Claim (Index 10):
A method of treating or preventing a glioma or for ameliorating effects of a glioma in a patient in need thereof, said method comprising administering to the patient a combination of:\n a first active agent selected from the group consisting of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein:\n Hal=Cl, F, Br or I \n W is either CR4 or \u2014N\u2550; \n X is either CR1 or \u2014N\u2550; \n Y is either CR2 or \u2014N\u2550; \n Z is either CR3 or \u2014N\u2550; \n R1 is selected from the group consisting of H, Hal, alkyl and O-alkyl; \n R2 is selected from the group consisting of H, Hal, alkyl, O-alkyl and C(O)R6; \n R3 is selected from the group consisting of H, Hal, alkyl and O-alkyl; \n R4 is selected from the group consisting of H, Cl, F, Br and I; \n R5 is selected from the group consisting of O\u2014R7 or H, alkyl, cycloalkyl, aralkyl, alkenyl, cycloalkenyl, heterocyclyl, aryl, C(O)-alkyl and C(O)-aryl, each of which is optionally substituted with one or more R8 groups; \n R6 is selected from the group consisting of OH, \u2550O, CN, COO-alkyl, aralkyl, heterocyclyl, SO2-alkyl, S alkyl, SO-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy; \n R7 is H or alkyl, cycloalkyl, aralkyl, alkenyl, cycloalkenyl, heterocyclyl, aryl, C(O)-alkyl, and C(O)-aryl, each of which is optionally substituted with one or more R8 groups; \n R8 is selected from the group consisting of H, OH, \u2550O, CN, COO-alkyl, aralkyl, heterocyclyl, SO2-alkyl, S alkyl, SO-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy; \n wherein said first active agent is in an oral, intravenous, epidural, intracerebral or intracerebroventricular route dosage form, and \n a second active agent, which is temozolomide, a prodrug thereof, or a pharmaceutically acceptable salt thereof, \n where the first and second active agents are administered simultaneously, separately or sequentially.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 86.0
- Lexical Diversity: 1.68085
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15316797', '14246558', '12878113', '13353713', '15467613']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.761630343066267
- 35 USC 102 Novelty (BERT): 0.5423079256153203
- Combined Prediction Score: 0.7396981013211724
- Mean Citation Score: 278.55366200000003
- Max Citation Score: 398.48172
- Similarity Product: 284.7706761103892

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test